tapebrief
INCY · Q3 2025
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

INCY · Q4 2025 Earnings

Incyte

Reported February 10, 2026

30-second summary

Q4 revenue grew 28% YoY to $1.51B and FY2025 net product revenue closed at $4.35B — beating the raised FY guide range ($4.23–4.32B) by ~$30M at the high end / ~$75M at midpoint. FY2026 product revenue guidance of $4.77–4.94B introduces an unusually aggressive Heme/Onc band ($800–880M, +40–50% YoY) and a 15% Opzelura midpoint, while Jakafi steps down to mid-single-digit growth — the first explicit signal that the post-LOE diversification narrative is now load-bearing in the numbers, not just the framing. Meury quantified the destination directly: "our core business excluding Jackify [Jakafi] has the potential to be as large as Jackify [Jakafi] is today by 2030."

Headline numbers

EPS

Q4 FY2025

$1.80

Revenue

Q4 FY2025

$1.51B

+28.0% YoY

Operating margin

Q4 FY2025

22.3%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$1.51B+28.0%$1.37B+10.5%
EPS$1.80—$2.26-20.4%
Operating margin22.3%—32.5%-1020bps

Guidance

Incyte substantially beat FY2025 revenue guidance (+$0.8B above high end) and raised FY2026 product revenue outlook with notably aggressive hematology/oncology growth expectations (+40–50% YoY).

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Total Net Product RevenueFY2025$4.23 - $4.32 billion$5.14 billion+$0.82 - $0.91 billion above guideBeat

New guidance

MetricPeriodGuideYoY
Jakafi net product revenueFY2026$3.22 - $3.27 billion+2.4-2.6% YoY
Opzelura net product revenueFY2026$750 - $790 million+15% YoY
Hematology and Oncology net product revenueFY2026$800 - $880 million+40-50% YoY
Total GAAP R&D and SG&A operating expensesFY2026$3.495 - $3.675 billion—
Total non-GAAP R&D and SG&A operating expensesFY2026$3.205 - $3.375 billion—

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
Jakafi$0.828B+7.0%
Opzelura$0.207B+28.0%
Monjuvi/Minjuvi$0.042B+28.0%
Iclusig$0.034B+25.0%
Total Net Product Revenue$1.22 billion—
Net Product Revenue Growth YoY20%—

Other KPIs

Q4 FY2025
SegmentQ4 FY2025
Milestone and Contract Revenue$100 million
Operating Margin22.3%
Non-GAAP Operating Income$451.4 million
Cash and Equivalents$3.6 billion
Non-GAAP EPS (Diluted)$1.80
Pivotal Clinical Trials Underway14

Management tone

Narrative arc: Q2 CEO repositioning around MPN dominance → Q3 commercial execution validating the reposition → Q4 the post-Jakafi diversification thesis is now quantified in guidance.

The single most consequential shift this quarter is that Meury has put a number on the X-Jakafi thesis: "our core business excluding Jackify [Jakafi] has the potential to be as large as Jackify [Jakafi] is today by 2030." In Q2 the equity story was repositioned around MPN dominance; in Q3 commercial execution started validating the reposition; in Q4 management has quantified the destination. A core business growing to ~$3B+ by 2030 is no longer a defensive framing of the 2029 LOE — it is an offensive growth thesis with a magnitude attached.

Pipeline confidence has stepped from breadth as opportunity (Q3) to breadth as the engine of a 2–3x topline. Verbatim: "Our pipeline has the breadth and depth to support top tier growth and the potential to 2 to 3x our top line over time...we will have 14 pivotal trials underway across seven assets by end of the year and multiple data catalysts." The Q3 brief flagged pipeline pruning under explicit go/no-go criteria; Q4 reframes what survived the pruning as the substrate of a multi-asset growth ramp. Fourteen pivotals across seven assets is a concrete unit of measurement against which 2026 execution will be judged.

Oncology positioning has hardened from exploratory programs to first-to-market white-space claims. Pablo: "If approved, 734 would represent the first G12D targeted therapy for the treatment of patients with pancreatic cancer." The Q3 brief noted a committed Phase III start for 890 in 1L MSS colorectal in 2026; in Q4 management is publicly naming the competitive positioning that justifies the capital allocation — including a Phase III initiation for 734 in 1L PDAC in Q1 2026.

NPM portfolio framing has tightened from "three targeted therapies in development" to a concrete regulatory roadmap: "We expect to initiate our Phase III trial evaluating 9A9 in second-line cholera-positive [CALR-positive] ET patients in mid-2026...our goal by the end of the decade is to have a treatment solution for every single patient with MPN." The 989 ET pivotal start in mid-2026 and MF pivotal start in 2H 2026 timing is now packaged inside an end-of-decade ambition.

Recurring themes management leaned on this quarter:

Pipeline maturation and late-stage visibilityCore business (X-Jackify) growth trajectory to $3-4B by 2030First-to-market potential in oncology (PDAC, colorectal)Myeloproliferative neoplasm (MPN) targeted therapy portfolio expansionFormulary access strategy as lever for sustainable growthMultiple pivotal trials and regulatory milestones in 2026

Risks management surfaced:

Opsalura prurigo nodolaris development paused due to FDA guidance requiring additional trialJackify generic entry in 2028-2029 requiring business transitionClinical execution risk on 14 pivotal trials across seven programs in 2026Competitive landscape in DLBCL (Polivia) and other oncology indicationsPovacitinib asthma Phase II data outcome dependent

Answers to last quarter's watch list

989 mutCALR Phase 1 MF readout in 2H 2025 — Phase 1 data from both ET and MF cohorts were presented at ASH in December; based on results, Phase III in 2L ET committed to mid-2026 and Phase III in 2L MF committed to 2H 2026. FDA Breakthrough Therapy Designation granted in December for Type 1 CALR mutation ET.
Resolved positively
Opzelura Q4 print — $207M in Q4 brings FY2025 to $678M, beating the $630–670M FY range that was reaffirmed twice. The FY2026 guide of $750–790M (+15% midpoint) reflects deliberate ASP discounting on formulary deals that will roll off in 2027.
Resolved positively
Ruxolitinib XR FDA bioequivalence submission — A response to the prior CRL has been submitted; regulatory decision and potential launch expected mid-2026.
Resolved positively
Niktimvo QoQ trajectory — $56M in Q4 vs $46M in Q3, +22% QoQ. Above the $55M threshold the prior brief flagged as required to sustain the Rezurock analog.
Resolved positively
First BD transaction — Cash grew from $2.9B to $3.6B QoQ; no transformational BD deal announced. Incyte entered an exclusive option agreement with Prelude Therapeutics in November for a mutant-selective JAK2V617F JH2 inhibitor program (option price $100M). Management is now framing growth via internal pipeline (14 pivotals across 7 assets) with BD positioned as "a multiplier.".
Continue monitoring
2026 OpEx framework — Hard numbers are now on the table: GAAP R&D+SG&A of $3.495–3.675B and non-GAAP $3.205–3.375B for FY2026. Against FY2025 non-GAAP base (R&D $1,897.9M + SG&A $1,280.4M = $3,178M), the FY2026 non-GAAP midpoint of $3,290M is +3.5% growth — management explicitly guided +4% at the GAAP midpoint. Within that envelope, R&D up ~10% (concentrated in the seven late-stage programs, ~80% of R&D spend) and G&A down ~10%, with deliberate reallocation to launch readiness. Status: Resolved positively (margin expansion thesis intact; OpEx growth lagging product revenue growth by ~6pp)

What to watch into next quarter

Heme/Onc segment trajectory vs the +40–50% FY2026 guide: Q1 prints near $190M (annualised to ~$760M, the low end) would validate; a print below $170M would force a credibility-testing mid-year revision. Track Niktimvo continuing >+20% QoQ specifically.

Opzelura ASP rolloff: management has now committed publicly that 2026 ASP impact rolls off in 2027. Watch whether Q1 commentary attaches a specific gross-to-net erosion number to FY2026, and whether the +15% growth at midpoint is being delivered via volume vs price.

Jakafi quarterly print vs mid-single-digit FY guide: the FY2026 guide implies Jakafi growth of ~+4–6%. A Q1 print at +7%+ would signal the guide is conservative; below +2% would signal genuine deceleration ahead of LOE.

Povorcitinib HS FDA filing acceptance: management committed to Q1 2026. A slip would be the first material regulatory miss of the Meury era.

Tafasitamab 1L DLBCL sBLA submission in 1H 2026: the gating event for the Heme/Onc growth ramp extending past 2026.

989 ET pivotal start in mid-2026 and MF pivotal start in 2H 2026: any slip undercuts the 2–3x topline framing.

734 (KRAS G12D) Phase III initiation in 1L PDAC in Q1 2026: confirmed for this quarter; track for on-time start.

Sources

  1. Incyte Q4 2025 press release: https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/incy-q42025xexx991.htm
  2. Incyte Q4 2025 earnings call transcript (prepared remarks and Q&A)
  3. Tapebrief Incyte Q3 2025 brief (cross-quarter trajectory, watch list, prior FY guide baseline)
  4. Tapebrief Incyte Q2 2025 brief (CEO repositioning context)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.